FGFR2-responsive self-assembled hydrogel releases its inhibitor to suppress the progression of endometriosis

Ma P, Panmei Ma, Wang S, Shen Wang, Zhang X, Xier Zhang, Li N, Nana Li, Xu L, Lu Xu, An Huang, Huang A, Wenjun Zhan, Zhan W, Zhao G, Guangfeng Zhao, Liu D, Dan Liu, Jiawen Sun, Sun J, Gaolin Liang, Liang G, Weng Q, Qiao Weng
Journal of controlled release : official journal of the Controlled Release Society · 2026 · vol. 395 , pp. 115007 · doi:10.1016/j.jconrel.2026.115007 · PMID:42114779 · W7160710535
article OA: closed public-domain-us
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

This study developed an FGFR2-responsive hydrogel that releases the inhibitor AZD4547 upon phosphorylation in endometriotic lesions, effectively suppressing lesion growth and metastasis in mice.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Fibroblast growth factor receptor 2 (FGFR2) has emerged as a highly promising therapeutic target due to its critical role in the pathogenesis and progression of endometriosis. To date, a variety of FGFR2 inhibitors have exhibited remarkable therapeutic efficacy against endometriosis in both preclinical studies and clinical trials. However, these small-molecule inhibitors suffer from drawbacks including poor targeting ability and high toxicity, and their direct administration has consequently limited their further clinical applications. In this study, a rationally designed hydrogenator, Nap-Phe-Phe-Phe-Asp-Asp-Asp-Tyr-OH (NapY), was co-assembled with the FGFR2 inhibitor AZD4547 (AZD) to construct an FGFR2-responsive hydrogel, aiming to achieve precise targeted therapy for endometriosis. Under the specific phosphorylation by FGFR2 which is highly expressed in endometriotic lesions, Nap-Y in Gel Y/AZD is phosphorylated and converted into a hydrophilic product, Nap-Phe-Phe-Phe-Asp-Asp-Asp-Tyr(H₂PO₃)-OH (Nap-Yp). This process further triggers the disassembly of the hydrogel, enabling the responsive release of AZD. In vitro experimental results demonstrated that the sustained release of AZD from Gel Y/AZD could effectively suppress the viability, migration and invasion of 12Z-FGFR2 cells by inhibiting the expression of FGFR2 and the phosphorylation levels of its downstream signaling pathway molecules. In vivo studies confirmed that compared with endometriosis model mice treated with free AZD, those treated with Gel Y/AZD exhibited significantly superior inhibitory effects on the growth and metastasis of ectopic lesions. It is anticipated that this research will expect to be applied in the clinical treatment of endometriosis in the near future.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides Benzamides

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Source provenance

europepmc
last seen: 2026-08-07T06:07:27.085738+00:00
openalex
last seen: 2026-08-07T06:00:58.240476+00:00
pubmed
last seen: 2026-08-07T06:03:00.141873+00:00
unpaywall
last seen: 2026-05-13T20:21:44.830810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine